CD28 and graft versus host disease: Of all 25 allografted patients (NHL, n = 8 and acute leukemia, n = 17) in our cohort treated with our in-house produced third-generation CAR T cells (recipient-derived; including both costimulatory domains 4-1BB and CD28), 11 patients had symptoms suggestive of GVHD.